Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium

Abstract Aims Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively. Methods and results Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study. Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardiovascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute risk reduction compared with individuals <6 ng/L of troponin I, whereas the relative risk reduction was similar. Conclusion In individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves prediction of cardiovascular death and cardiovascular disease.

[1]  Deepak L. Bhatt,et al.  Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. , 2015, The New England journal of medicine.

[2]  Olga V. Demler,et al.  Tests of calibration and goodness‐of‐fit in the survival setting , 2015, Statistics in medicine.

[3]  J. D. de Lemos,et al.  Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. , 2015, Clinical chemistry.

[4]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[5]  J. Manson,et al.  B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. , 2014, Journal of the American College of Cardiology.

[6]  G. Felker,et al.  N-terminal pro-B-type natriuretic peptide: a risk predictor for all. , 2014, Journal of the American College of Cardiology.

[7]  Frank Kee,et al.  BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries , 2014, European Journal of Epidemiology.

[8]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[9]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[10]  Marco Geraci,et al.  Linear Quantile Mixed Models: The lqmm Package for Laplace Quantile Regression , 2014 .

[11]  Marco Geraci,et al.  Linear quantile mixed models , 2013, Statistics and Computing.

[12]  Paolo Giordani,et al.  Three-Way Component Analysis Using the R Package ThreeWay , 2014 .

[13]  V. Salomaa,et al.  Comparison of Three Troponins as Predictors of Future Cardiovascular Events – Prospective Results from the FINRISK and BiomaCaRE Studies , 2014, PloS one.

[14]  R. Schnabel,et al.  Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study , 2014, Clinical Research in Cardiology.

[15]  A. Keech,et al.  Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). , 2014, Journal of the American College of Cardiology.

[16]  V. Salomaa,et al.  High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. , 2014, European heart journal.

[17]  R. Prager,et al.  PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. , 2013, Journal of the American College of Cardiology.

[18]  C. Watson,et al.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.

[19]  S. Solomon,et al.  Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. , 2013, Journal of the American College of Cardiology.

[20]  Shah Ebrahim,et al.  [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[21]  Fred S Apple,et al.  Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. , 2012, Clinical chemistry.

[22]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[23]  N. Cook,et al.  Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus: The Women's Health Study , 2011, Circulation.

[24]  S. Yusuf,et al.  Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. , 2011, Kidney international.

[25]  Eric Boerwinkle,et al.  Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011, Circulation.

[26]  Holly Janes,et al.  Measuring the Performance of Markers for Guiding Treatment Decisions , 2011, Annals of Internal Medicine.

[27]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[28]  A. Khera,et al.  Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.

[29]  M. Zhan,et al.  Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. , 2010, JAMA.

[30]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[31]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[32]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[33]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[34]  Georg Endler,et al.  C-reactive protein and all-cause mortality in a large hospital-based cohort. , 2008, Clinical chemistry.

[35]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[36]  V. Salomaa,et al.  Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. , 2005, American journal of epidemiology.

[37]  Laura Antolini,et al.  Inference on Correlated Discrimination Measures in Survival Analysis: A Nonparametric Approach , 2004 .

[38]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[39]  V. Salomaa,et al.  Decline in Out-of-Hospital Coronary Heart Disease Deaths Has Contributed the Main Part to the Overall Decline in Coronary Heart Disease Mortality Rates Among Persons 35 to 64 Years of Age in Finland: The FINAMI Study , 2003, Circulation.

[40]  J. Fox Effect Displays in R for Generalised Linear Models , 2003 .

[41]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[42]  Jason Wittenberg,et al.  Clarify: Software for Interpreting and Presenting Statistical Results , 2003 .

[43]  Joseph G. Ibrahim,et al.  A partial correlation coefficient and coefficient of determination for multivariate normal repeated measures data , 2001 .

[44]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[45]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[46]  M. Pencina,et al.  Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. , 2014, Annals of Internal Medicine.

[47]  Jennifer G. Robinson,et al.  Reply: 2013 ACC/AHA guideline on the assessment of cardiovascular risk. , 2014, Journal of the American College of Cardiology.

[48]  B. Gersh C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010 .